Immune response data for ino-3107 to be presented as a poster at american association for cancer research immuno-oncology (aacr-io) conference

Poster will describe loss of detectable hpv-6 in recurrent respiratory papillomatosis patients following treatment with ino-3107 plymouth meeting, pa. , feb. 10, 2025 /prnewswire/ --  inovio (nasdaq:ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that an abstract describing the immunological activity of ino-3107 will be presented as a poster at the following scientific conference: american association for cancer research – immuno-oncology discovery and innovation in cancer immunology: revolutionizing treatment through immunotherapy (february 23-26, 2025) poster entitled: "loss of detectable hpv-6 following induction of emergent t cells in patients with durable complete clinical response to treatment for recurrent respiratory papillomatosis using ino-3107" the abstract will be made available on inovio's website following the conference.
INO Ratings Summary
INO Quant Ranking